LeMaitre Vascular 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Q3 organic sales grew 12%, comprising 7% price growth and 5% unit growth; reported sales growth was 11%, including a $440,000 negative foreign-exchange impact.
- Grafts grew 20% and shunts grew 14%; Artegraft sales increased 18% and Restoraphil Allograft revenues increased 34%.
- Sales increased 18% in EMEA, 9% in the Americas, and 5% in APAC.
- Q3 gross margin was 71.7%, up 90 basis points year over year; excluding a $0.5 million inventory reserve for the FasTip discontinuation, gross margin was 72.4%, up 160 basis points.
- Operating expenses were $31 million, up 18% year over year, as sales rep count rose 13% to 171 at quarter-end; operating income was $17.7 million and operating margin was 26%.
- Net income was $15 million and fully diluted EPS was $0.65; free cash flow was $19.7 million, and the company ended September with $390 million of cash and investments.
- LeMaitre acquired vascular assets from B. Braun for total consideration of $19.2 million, including an initial payment of $16.6 million and a deferred payment of $2.6 million; the products recorded $9.4 million of sales in 2025.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome to the LeMaitre Vascular Q3 2026 financial results conference call. As a reminder, today's call is being recorded. At this time, I would like to turn the call over to Mr. Dorian LeBlanc, Chief Financial Officer of LeMaitre Vascular.
Please go ahead, sir. Good afternoon, and thank you for joining us on our Q3 2026 conference call.
With me on today's call is our CEO, George LeMaitre. Before we begin, I will read our safe harbor statement. Today, we will be making some forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995, the accuracy of which is subject to risk and uncertainties. Wherever possible, we will try to identify those forward-looking statements by using words such as believe, expect, anticipate, pursue, forecast, might, and similar expressions. Our forward-looking statements are based on our estimates and assumptions as of today, November 4, 2026, and should not be relied upon as representing our estimates or views on any subsequent date.
Please refer to the cautionary statement regarding forward-looking information and the risk factors in our most recent 10-K and subsequent SEC filings, including disclosure of the factors that could cause results to differ materially from those expressed or implied. During this call, we will discuss non-GAAP financial measures such as organic sales growth. A reconciliation of GAAP to non-GAAP measures discussed in this call is contained in the associated press release and in the investor relations section of our website, www.lemaitre.com. I will now turn the call over to George LeMaitre.
Thanks, Dorian. Sales grew 12% organically in Q3, 7% price, and 5% units. Grafts grew 20% and shunts 14%. Biologics continued to outpace the rest of our portfolio, as Artegraft was up 18% and RestoreFlow allografts 34%. Geographically, EMEA sales increased 18%, the Americas 9%, and APAC 5%. On October 14, we acquired several devices from B. Braun, polyester and silver-coated vascular grafts, valve cutters, and vein strippers. This is our third polyester graft acquisition since 2007, and we look set to become number three in worldwide share ex-Japan. We have always wanted to offer silver-coated vascular grafts, as they are designed to resist infection. The acquired portfolio posted 2025 sales of $9.4 million, all outside North America. 65% of sales were in Europe, including 21% in Germany, our second-largest market. While the sales transition will take about two years, this acquisition is right out of our playbook.
We acquire niche vascular and cardiac products and grow them through our global sales channel. As for Artegraft, we are investing in the product in several ways. Number one, more international approvals. Number two, increased lengths for leg bypasses. Number three, building out our commercial infrastructure and sales force. Q3 international Artegraft sales were $3 million, and we continue to expect full-year sales of more than $11 million. In Q3, we received approvals in Brazil and Saudi Arabia, bringing us to 60 countries. We expect 2027 approvals in Korea and India. We plan to apply to the PMDA in Japan this quarter, hoping for 2029 or 2030 approval. We are also developing long Artegrafts for leg bypasses. Unfortunately, our Artegraft packaging is too short for these long grafts.
We plan to submit for U.S. and CE mark long tube approval in Q4 2026, for sales could start in H2 2027. on October 7, we attended an encouraging FDA virtual meeting regarding our New Jersey Artegraft facility. The agency is reviewing our responses to their observations. The observations from the two FDA inspections have not disrupted our ability to produce, ship, or invoice. an FDA reinspection is likely in 2027. RestoreFlow allograft revenues grew 34% in Q3. We are approved to distribute these cadaver tissues in six countries: the U.S., Canada, New Zealand, the United Kingdom, Austria, and Germany. We are actively working to gain approvals in four countries in 2027: Holland, Ireland, Spain, and Switzerland. We still plan to close our Chicago RestoreFlow facility this year and fully transfer production to Burlington. We continue to expand our commercial infrastructure.
Rep count increased by 19 year-over-year to 171 at quarter's end. Our American and German territories continue to grow, requiring us to split territories. We now plan to open a Polish office and warehouse in Q1 2027. We also plan to open a Malaysian office and warehouse in 2027. Indeed, seven new or larger LeMaitre International warehouses are opening in 2026/2027. These offices place LeMaitre products closer to our hospital customers and provide local customer service. We also recently expanded our Burlington footprint by adding a 30,000 sq ft building. We gain access to the building in July 2027 and expect to use the space to consolidate our Burlington manufacturing operations and provide capacity to integrate manufacturing from acquisitions. Per our recent eight-K, 2026 will be Dave Roberts' last year as our President, though he will remain on our board as elected by our shareholders.
In his 30 years at LeMaitre, Dave navigated our 2006 IPO as CFO and spearheaded 26 acquisitions. Of course, these are big shoes to fill professionally. We have begun recruiting additional senior-level biz dev executives. In the short run, I will be heading up our biz dev group, and we will remain an acquisitive company. In other personnel news, I would like to welcome Tarek Pachuca to LeMaitre as our new Global Head of Marketing and Worldwide Export. Tarek joined in August after 16 years at Terumo Aortic, where he was the Chief Commercial Officer. Terumo Aortic sells approximately $375 million a year of polyester grafts and stent grafts, and has a common call point with LeMaitre Vascular and cardiac surgeons. To conclude, 12% organic growth was driven by price and unit growth, the international autograft launch, RestoreFlow growth, and our expanding sales force.
Our 26% Q3 op margin, as well as our 27% ROIC, underscores our underlying profitability. Full-year guidance implies 11% organic sales growth, 11% reported sales growth, and 18% EPS growth. I'll now turn the call over to Dorian.
Thanks, George. LeMaitre's Q3 organic revenue growth of 12% consisted of 7% price and 5% units. Our Q3 reported growth of 11% was negatively impacted $440,000 by foreign exchange due to the year-over-year strengthening of the U.S. dollar. Our reported Q3 2025 financial results included a $4.8 million Employee Retention Tax Credit, and the following year-over-year comparisons all exclude this benefit. In Q3 2026, gross margin was 71.7%. The 90 basis point increase year-over-year was driven primarily by higher ASPs and reduced shipping costs, offset by a $0.5 million inventory reserve for a product discontinuation. As part of our ongoing portfolio management process, in Q3, we announced the discontinuation of FAS-TIP. Excluding this inventory charge, gross margin for the quarter was 72.4%, up 160 basis points versus Q3 2025.
Operating expenses in Q3 2026 were $31 million, an increase of 18% versus Q3 2025, as sales rep count increased by 13% year-over-year to 171 at quarter's end. In addition, R&D spending increased $1.1 million year-over-year, driven by process improvement programs and the RestoreFlow transfer expenses. Q3 2026 operating income was $17.7 million, resulting in a 26% operating margin. Net income was $15 million, and fully diluted EPS was $0.65. Free cash flow, cash from operations less capital expenditures, was $19.7 million, a sequential increase of $6 million from Q2 2026. The company ended September with $390 million of cash and investments. We acquired a portfolio of vascular assets from B. Braun in October for total consideration of $19.2 million. The consideration includes an initial payment of $16.6 million and a deferred payment of $2.6 million to be paid on the one-year anniversary of the closing date.
The 2025 sales of these products by B. Braun were $9.4 million. As these products have historically been sold under contracts, including contracts that bundle other non-acquired B. Braun products, this commercial transition has some complexity and is expected to take 18-24 months. During the commercial transition period, B. Braun will continue to directly supply customers until their customer agreements conclude or the contracts can be transferred to LeMaitre. LeMaitre will be entitled to profit sharing on the continued direct B. Braun sales. However, under U.S. GAAP, LeMaitre will not record revenue related to those sales until the customer orders are fulfilled directly by LeMaitre. During Q4, we expect sales will be transacted predominantly by B. Braun, and we anticipate recording revenue for direct sales of approximately $150,000, with no net impact on operating income. In addition, B. B. Braun will continue to manufacture the products during a four-year supply agreement while LeMaitre works to transfer manufacturing to Burlington.
We may face back orders during this period, but after we transfer production to Burlington, we look forward to instilling LeMaitre's no back order commitment to these products. We believe the acquired products fit well in the bag of our expanding global sales force and aligns well with our European commercial capabilities, and the acquired manufacturing processes align with the competencies of our U.S.-based polyester graft manufacturing teams. We've been manufacturing polyester grafts in Burlington since 2011. For 2026, we have reiterated our 11% organic revenue growth guidance for the year. Our reported revenue guidance of $275.8 million reflects the recent strengthening of the U.S. dollar, with a euro-to-USD rate of 1.12 compared to 1.15 at our August earnings call.
We anticipate a full-year gross margin of 72.1%, a 170 basis point improvement from adjusted 2025, and full-year operating income of $75.4 million for a 27% operating margin in 2026. We also updated our guidance on fully diluted earnings per share to $2.80, up 18% from adjusted 2025. Our guidance includes the modest 2026 impact of the B. Braun acquisition. With that, we'll pass it to the operator for questions.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
